Abstract. RASSF2, a member of the RAS association domain family 1 (RASSF1), is a candidate tumor suppressor gene (TSG) that is silenced by promoter hypermethylation in several human cancers. In this study, we examined the expression of RASSF2 mRNA and the promoter methylation status in lung cancer cell lines and in tumor samples of 106 primary nonsmall cell lung cancers (NSCLCs) by methylation-specific PCR. RASSF2 expression was absent in 26% of small cell lung cancers (SCLCs; n=27 lines) and 50% of NSCLCs (n=42 lines). Promoter methylation of RASSF2 was found in 18% of the SCLC cell lines (n=22) and 62% of the NSCLC cell lines (n=26), and the methylation status was tightly associated with the loss of RASSF2 expression. RASSF2 expression was restored by treatment with 5-aza-2-deoxycytidine and/or trichostatin-A in the NSCLC cell lines which were absent of the expression. RASSF2 methylation was found in 31% of primary NSCLC tumors, and methylation was more frequent in the specimens from non-smokers (18 of 40, 45%) than in the specimens from smokers (15 of 66, 23%, P=0.014). We also examined the association of RASSF2 methylation with mutations of KRAS and EGFR and with promoter hypermethylation of RASSF1A; however, we could not find a significant association between RASSF2 methylation and these genetic and epigenetic changes. Our results indicate that aberrant methylation of the RASSF2 gene with the subsequent loss of RASSF2 expression plays an important role in the pathogenesis of lung cancers.
Introduction
Recent advances in molecular genetics have revealed that multiple alterations accumulate in a multi-step manner via both genetic and epigenetic mechanisms during the process of lung carcinogenesis (1) . Aberrant DNA hypermethylation of CpG sites in the promoter regions of a gene is a tumoracquired epigenetic event that results in the inactivation of tumor suppressor genes (TSGs) (2) . The aberrant promoter hypermethylation of several TSGs is frequently observed in lung cancers and seems to play an important role in lung cancer development (3) .
RAS family genes encode small GTPase proteins involved in the signal transduction of extracellular signals (4) . RAS proteins interact with a wide spectrum of regulators and downstream effectors to produce various cellular responses, including cell proliferation, differentiation, and apoptosis (4) . RAS association domain family 1 (RASSF1) has been identified as a potential tumor suppressor that can serve as a RAS effector (5, 6 ). RASSF1A, a major transcript of RASSF1, is frequently inactivated due to promoter hypermethylation in a variety of human cancers, including lung cancer (5, 7, 8) . RASSF2, which is located at 20p13, was recently identified as a third member of the RASSF1 family (9) . The RASSF2 protein binds to KRAS in a GPT-dependent manner via the RAS effector domain, but it displays only a weak interaction with HRAS (9) . Some studies have reported that RASSF2 expression was frequently down-regulated in lung cancer cell lines, and the forced expression of RASSF2 inhibited the growth of tumor cells and promoted both cell cycle arrest and apoptosis (9) . RNAi-mediated silencing of RASSF2 expression enhanced the anchorage-independent growth of cells transformed by KRAS (10) . Moreover, the RASSF2 gene was silenced via promoter hypermethylation in cancers of the colon, stomach, and nasopharynx (10) (11) (12) . These results indicate that the epigenetic inactivation of the RASSF2 gene plays a role in the pathogenesis of various human cancers. However, it is not clarified whether RASSF2 is inactivated by promoter hypermethylation in lung cancers. Therefore, we examined the expression and promoter methylation status of RASSF2 in lung cancer cell lines and primary NSCLC. We also examined the correlation of RASSF2 methylation with clinicopathological features and KRAS and EGFR mutations and RASSF1A methylation in patients with primary NSCLC.
Materials and methods
Cell lines, tumor samples and DNA preparation. Lung cancer cell lines used in the present study included the following: 27 small cell lung cancers (SCLCs) (NCI-H82, -H187, -H209,  -H289, -H345, -H378, -H524, -H526, -H740, -H865, -H889,  -H1045, -H1092, -H1184, -H1238, -H1339, -H1607, -H1618,  -H1672, -H1963, -H2107, -H2141, -H2171, -H2227, HCC33,  HCC970 and N417) ; and 42 non-small cell lung cancers (NSCLCs) (NCI-H23, -H157, -H322, -H358, -H460, -H520, -H661, -H1264, -H1299, -H1395, -H1437, -H1648, -H1666, -H1792, -H1819, -H1993, -H2009, -H2077, -H2087, -H2106, -H2122, -H2126, -H2347, -H2882, -H2887, -H3255, HCC15, HCC44, HCC78, HCC95, HCC193, HCC366, HCC461, HCC515, HCC827, HCC1171, HCC1195, HCC1359, HCC1883, HCC2450, A427 and A549). Cells were cultured in RPMI medium 1640 (Sigma, St. Louis, MO) supplemented with 10% bovine serum. Tumors were obtained from 106 patients with primary NSCLC who underwent surgery between 2001 and 2003 at the Gunma University School of Medicine Hospital, Gunma, Japan. Tumor samples were immediately frozen at surgery and kept at -80˚C until DNA extraction. Genomic DNAs were prepared by the method described previously (13) or by a DNeasy kit (Qiagen, Chatworth, CA), according to the manufacturer's instructions.
Reverse transcription-polymerase chain reaction (RT-PCR).
RT-PCR was performed as described previously (14) . Briefly, total RNA was extracted from cells, and cDNA was synthesized using 2 μg of total RNA with the Superscript II firststrand synthesis using oligo (dT) primer System (Invitrogen, Carlsbad, CA). Aliquots of the reaction mixture were used for the subsequent PCR amplification. Primer sequences used were 5'-AAG ACA TCC GTG TTC ACA CC-3' and 5'-TCG TTC TCA TGG CTC AGA TT-3' for RASSF2 mRNA (462 bp). PCR was performed for 35 cycles, each of which consisted of denaturation at 94˚C for 30 sec, annealing at 55˚C for 30 sec, and extension at 72˚C for 1 min, followed by a final 10-min extension at 72˚C. The products were separated by electrophoresis on 2% agarose-TBE gels, and the bands were visualized by ethidium bromide staining. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control to confirm the success of the reaction.
5-Aza-2'-deoxycytidine (5-aza-dC) and/or trichostatin A (TSA)
treatment. Cells were treated with 5-aza-dC and/or TSA as described (15) . Briefly, cells were incubated for the first 48 h in a medium containing 10 μM 5-aza-dC (Sigma) or 0.5 μM TSA (Wako, Tokyo). For the study of synergism, 10 μM 5-aza-dC was present in culture for 48 h and then for another 24 h with the addition of 0.5 μM TSA. Total RNA was then isolated with Rneasy minikit (Qiagen), and RT-PCR analysis was carried out with the RASSF2 oligonucleotide primers.
Methylation-specific PCR (MSP).
Bisulphite modification of DNA was performed by BisulFast DNA modification kit (Toyobo Co., Ltd., Life Science Department, Osaka, Japan), according to the manufacturer's instructions. The modified DNA was used as a template for MSP with primers specific for either the modified methylated or the modified unmethylated RASSF2 promoter sequences. Treated DNAs were PCR-amplified with the following primer sets including CpG island of RASSF2 as described (11): 5'-CGA AGG AGG GCG GGG AGATC-3' (sense) and 5'-TCC GCC GCC GTC TTC TAA ACG-3' (antisense) for the methylated RASSF2 sequence (148 bp); and 5'-GTT TTG AAG GAG GGT GGG GAG ATT-3' (sense) and 5'-AAT CCA CCA CCA TCT TCT AAA CA-3' (antisense) for the unmethylated RASSF2 sequence (154 bp). PCR amplification consisted of 15 min at 95˚C, followed by 45 cycles of 15-sec denaturation at 95˚C, 15 sec of annealing at 55˚C, 30 sec of extension at 72˚C, with final extension at 72˚C for 7 min for the methylated and unmethylated primers using HotStar Taq DNA polymerase (Qiagen). PCR products were separated in 3% agarose gels with ethidium bromide and visualized under UV illumination. As a positive control, SssI methylase (New England bioLabs, Table I . Incidence of loss of RASSF2 mRNA expression in lung cancer cell lines. 
Inc., Beverly, MA, USA) was used to methylate the immortalized human bronchial epithelial cell line BEAS-2B, and was modified by sodium bisulphate as described above.
Methylation analysis of the RASSF1A and mutational analyses of the KRAS and EGFR gene. Mutations of KRAS
and EGFR, and promoter methylation of RASSF1A were examined as reported previously (16, 17) . Briefly, RASSF1A methylation was analyzed by methylation-specific PCR method using genomic DNAs treated by sodium bisulfite (16) . Four exons (exons 18-21), which code for tyrosine kinase domain of the EGFR gene, and codons 12 and 13 of the KRAS gene were amplified by PCR with EGFR-and KRAS-specific oligonucleotide primers as described (17) . PCR products were sequenced with ABI 310 Genetic Analyzer (Applied Biosystems, Foster City, CA).
Statistical analysis.
Fisher's exact test was used to examine the association of two categorical variables. A P-value of <0.05 was considered to be statistically significant. Statistical analysis was performed using StatView J-4.5 for Macintosh.
Results

Expression of the RASSF2 gene in lung cancer cell lines.
We first examined the expression of RASSF2 mRNA in lung cancer cell lines (Fig. 1a) . RASSF2 expression was absent in 26% of SCLC cell lines (n=27) and 50% of NSCLC cell lines (n=42 ; Table I ). In the analysis of subtypes of NSCLCs, the expression was absent in 60% of adenocarcinomas (n=25), 60% of squamous cell carcinomas (n=5), 33% of large cell carcinomas (n=6), 20% of non-small cell carcinomas (n=5), and one adenosquamous cell carcinoma. The frequency of loss of RASSF2 expression was significantly higher in NSCLCs than SCLCs (P=0.04).
Promoter hypermethylation of the RASSF2 gene. The methylation status of the RASSF2 gene was determined by MSP in 22 SCLC cell lines and 26 NSCLC cell lines (Fig. 1b , Table II ). The hypermethylation of RASSF2 was detected in 18% of SCLCs and 62% of NSCLCs. Three SCLCs and 15 NSCLCs that lacked RASSF2 expression exhibited the hypermethylation, whereas the hypermethylation were not detected in 15 SCLCs and 8 NSCLCs that expressed RASSF2. The frequency of RASSF2 methylation was significantly higher in NSCLCs than in SCLCs (P=0.002).
There was a significant correlation between RASSF2 methylation and loss of RASSF2 expression in both SCLCs and NSCLCs (P=0.04 and P<0.001, respectively). To assess whether the loss of RASSF2 expression in lung cancer was a result of aberrant methylation and/or histone deacetylation, we examined the effect of the demethylating agent 5-aza-dC and/or histone deacetylase inhibitor TSA on the RASSF2 expression in two cell lines (NCI-H520 and -H460) that lacked RASSF2 expression (Fig. 2) . The expression was restored by the treatment with 5-aza-dC and/or TSA in two cell lines (NCI-H520 and -H460) in which aberrant methylation was detected by MSP.
Correlation between RASSF2 methylation and clinicopathological features in primary NSCLC tumors.
One hundred and six primary NSCLC tumor samples were examined for RASSF2 methylation by MSP (Fig. 3) . RASSF2 methylation was detected in 31% of the NSCLC tumors. All tumor samples Table II . Correlation between expression and methylation of RASSF2 in lung cancer cell lines. --------------------------------------------------------------------------------------------------- - had unmethylated alleles. We then analyzed the relationship between the methylation of RASSF2 and the clinicopathological characteristics of these patients (Table III) . RASSF2 methylation was significantly higher in non-smokers (18/22, 82%) than in smokers (15/51, 29%; P=0.014) than in smokers, and was marginally higher in tumors with pleural involvement (19/29, 66%) than in those without pleural involvement (12/41, 29%; P=0.052). There was no significant correlation of RASSF2 methylation with age, gender, stage, pathology, lymphatic permeation, or vascular invasion. We also analyzed the association of RASSF2 methylation with mutations of KRAS and EGFR, and RASSF1A methylation (Table III) . However, we could not find significant association between RASSF2 methylation and abnormalities of these genes.
-----------------------------------------------------------------------------------------------------
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Discussion
We demonstrated here that the expression of the RASSF2 gene was absent in a substantial number of lung cancer cell lines, especially NSCLCs. A previous study showed that the lack of RASSF2 expression was found in six of seven NSCLC cell lines (9) . Therefore, we could confirm that the lack of RASSF2 expression was frequently observed in NSCLCs using a larger number of cell lines. In addition, we also demonstrated that the lack of RASSF2 expression was observed in SCLC cell lines. These results indicate that RASSF2 is down-regulated in both NSCLC and SCLC.
To analyze the mechanism of the negative expression of the RASSF2 gene, we focused on examining the promoter hypermethylation of RASSF2 in a panel of lung cancer cell lines and primary NSCLC tumors. Our MSP results showed that the RASSF2 promoter region was subject to methylation in 42% of the lung cancer cell lines with a significant correlation between methylation status and RASSF2 expression, and the frequency of methylation was higher in NSCLCs than SCLCs. Furthermore, the demethylating agent 5-aza-dC restored RASSF2 expression in lung cancer cell lines. We also observed RASSF2 methylation in 31% of primary NSCLC tumors. These results indicate that RASSF2 is frequently hypermethylated in lung cancers (predominantly NSCLC), and promoter methylation functionally silences the expression of RASSF2. We also examined the effect of a histone deacetylase (HDAC) inhibitor, TSA, to assess whether the loss of RASSF2 expression in lung cancers was the result of histone deacetylation. TSA also restored the RASSF2 expression in these lung cancer cell lines, while the combined treatment of 5-aza-dC and TSA did not increase its expression. It is therefore possible that both histone deacetylation and promoter methylation play roles in silencing RASSF2 expression; however, these two events occur independently.
We analyzed the correlation between the RASSF2 methylation status and the clinicopathological features of NSCLC patients, and demonstrated that methylation was significantly more frequent in non-smokers. Although KRAS mutations and the aberrant methylations of genes such as p16 INK4a , RASSF1A, and APC in lung cancers have been closely related to smoking history (10) (11) (12) 18) , there are few reports of genetic or epigenetic alterations related to the absence of a history of smoking. Recently, we found that the Table III . Correlation of RASSF2 methylation with clinicopathological characteristics of patients with non-small cell lung cancer. - ------------------------------------------------ frequency of aberrant methylation of the RUNX3 gene was higher in non-smokers than in smokers (19) . The reason for this finding is unclear, but it is possible that some carcinogens other than those in tobacco smoke induce these molecular changes. EGFR mutations in the tyrosine kinase domain were the first genetic alterations that were observed to predominantly occur in NSCLC in non-smokers (20) . In this study, we could not find a significant association between EGFR mutations and RASSF2 methylation (Table  III) , suggesting that there are distinct roles for RASSF2 and EGFR in the pathogenesis of NSCLC arising in non-smokers.
RASSF2, as well as RASSF1A, was identified as a negative regulator of KRAS (9) . Because the activation of the RAS signaling pathway mediated by mutant KRAS is a wellknown molecular abnormality leading to the malignant transformation of NSCLC (1,4) , RASSF2 could function as a tumor suppressor by inhibiting the activated RAS signaling. Akino et al showed that the siRNA-mediated silencing of RASSF2 enhanced the anchorage-independent growth ability of cells transformed by KRAS, and KRAS mutations were more frequently observed in colorectal tumors with RASSF2 methylation in comparison to those without methylation (10) . This suggests that the inactivation of the RASSF2 gene plays a role in tumorigenesis by enhancing the KRAS-mediated malignant transformation. However, Hessen et al reported an inverse association between KRAS mutations and RASSF2 methylation, suggesting that these alterations are mutually exclusive (18) . The relationship between RASSF2 and KRAS in the process of tumorigenesis is therefore still obscure. Because our series included only two tumors with KRAS mutations, further studies using a larger number of KRAS mutation-positive NSCLC samples will be necessary to clarify this issue.
In conclusion, aberrant methylation of the RASSF2 gene and the subsequent loss of RASSF2 expression was a common event in lung cancers, predominantly in NSCLCs. Although the mechanism by which RASSF2 functions as a tumor suppressor remains unclear, the inactivation of the RASSF2 gene via promoter hypermethylation may contribute to the pathogenesis of lung cancer. Our analysis of the correlation between RASSF2 methylation and the clinicopathological features of 106 NSCLC tumor demonstrated that the frequency of methylation was significantly higher in tumors from nonsmokers than in tumors from smokers. This finding suggests that RASSF2 may play a role in the pathogenesis of NSCLC arising in non-smokers.
